Fintel reports that on January 12, 2026, Barclays downgraded their outlook for Insulet (NasdaqGS:PODD) from Equal-Weight to ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. Insulet Corporation is one of them. Insulet Corporation (NASDAQ:PODD) is a global leader in tubeless insulin ...

Investors in Insulet Corp (Symbol: PODD) saw new options become available this week, for the August 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PODD ...

PODD gains momentum as Omnipod 5 adoption accelerates, margins scale, and earnings estimates rise despite macro and concentration risks.

Insulet (NASDAQ:PODD) has outperformed the market over the past 15 years by 11.66% on an annualized basis producing an average annual return of 23.78%. Currently, Insulet has a market capitalization ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks ...

As of October 22, 2024, the average one-year price target for Insulet is $252.59/share. The forecasts range from a low of $186.85 to a high of $299.25. The average price target represents an increase ...

Insulet Corporation (NASDAQ:PODD) ranks among the best medical device stocks to invest in. Canaccord Genuity maintained its Buy rating on Insulet Corporation (NASDAQ:PODD) and boosted its price target ...

(Photo by Kirk Mckoy/Los Angeles Times via Getty Images) When it comes to surgical innovation, Intuitive Surgical (NASDAQ: ISRG) often dominates investor attention. But Insulet Corporation (NASDAQ: ...

Insulet Corporation (NASDAQ:PODD) is one of the best growth stocks to buy in 2026. On December 18, Truist lowered the firm’s price target on Insulet to $390 from $412 with a Buy rating on the shares.

Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over ...